Advanced in Carney Complex

Dr. Gregory Cote

Hematology Oncology | Hematology | Oncology
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Advanced in Carney Complex
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gregory Cote is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Cote and is rated as an Advanced provider by MediFind in the treatment of Carney Complex. His top areas of expertise are Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Chordoma, Synovial Sarcoma, and Tissue Biopsy.

His clinical research consists of co-authoring 77 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Newton-Wellesley Hospital
Massachusetts General Hospital
Cooley Dickinson Hospital Inc,the
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO

Locations

MASSACHUSETTS GENERAL PHYSICIANS ORGANIZATION INC
55 Fruit St, Boston, MA 02114

Additional Areas of Focus

Dr. Cote has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Enrollment Status: Recruiting
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: INBRX-109
Study Phase: Phase 2
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drugs: Lurbinectedin, Irinotecan
Study Phase: Phase 1/Phase 2
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms
Enrollment Status: Completed
Publish Date: March 06, 2025
Intervention Type: Biological
Study Drug: MGD019 Bispecific DART Protein Binding PD-1 and CTLA-4
Study Phase: Phase 1
Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.
Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Biological
Study Drug: TAEK-VAC-HerBy
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
A Phase 1b/2 Trial of Lurbinectedin Plus Doxorubicin in Leiomyosarcoma
A Phase 1b/2 Trial of Lurbinectedin Plus Doxorubicin in Leiomyosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2024
Intervention Type: Drug
Study Drugs: Lurbinectedin, Doxorubicin
Study Phase: Phase 1/Phase 2
A Pilot Phase 2 Study of Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
A Pilot Phase 2 Study of Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
Enrollment Status: Active_not_recruiting
Publish Date: November 08, 2024
Intervention Type: Drug
Study Drug: Eribulin
Study Phase: Phase 2
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: TP-1287
Study Phase: Phase 1
A Phase II Study of M6620 (VX-970) in Selected Solid Tumors
A Phase II Study of M6620 (VX-970) in Selected Solid Tumors
Enrollment Status: Completed
Publish Date: July 07, 2023
Intervention Type: Drug
Study Drug: M6620
Study Phase: Phase 2
A Phase 2 Trial of BN-Brachyury and Radiation Therapy in Patients With Advanced Chordoma
A Phase 2 Trial of BN-Brachyury and Radiation Therapy in Patients With Advanced Chordoma
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Biological
Study Drug: BN-Brachyury plus Radiation
Study Phase: Phase 2
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M4344 (Formerly VX-803) as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M4344 (Formerly VX-803) as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: March 16, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors
A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors
Enrollment Status: Completed
Publish Date: May 19, 2022
Intervention Type: Biological
Study Phase: Phase 1
Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms
Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms
Enrollment Status: Terminated
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1
View 14 Less Clinical Trials

75 Total Publications

SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma.
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma.
Journal: Future oncology (London, England)
Published: February 11, 2025
Similar Doctors
Experienced in Carney Complex
Dr. Elizabeth P. Walsh
Hematology Oncology | Hematology | Oncology
Experienced in Carney Complex
Dr. Elizabeth P. Walsh
Hematology Oncology | Hematology | Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (0.1 mi)
617-724-0287
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elizabeth Walsh is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Walsh has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Carney Complex. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Familial Colorectal Cancer, and Pancreatic Cancer. Dr. Walsh is currently accepting new patients.

Experienced in Carney Complex
Dr. Priscilla A. Merriam
Hematology Oncology | Hematology | Oncology
Experienced in Carney Complex
Dr. Priscilla A. Merriam
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (2.7 mi)
617-632-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Priscilla Merriam is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Merriam and is rated as an Elite provider by MediFind in the treatment of Carney Complex. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Alveolar Soft Part Sarcoma, and Epithelioid Sarcoma. Dr. Merriam is currently accepting new patients.

Experienced in Carney Complex
Dr. Zachary S. Spigelman
Hematology Oncology | Hematology | Oncology
Experienced in Carney Complex
Dr. Zachary S. Spigelman
Hematology Oncology | Hematology | Oncology

Lahey Clinic Inc

1 Essex Ctr Dr, 
Peabody, MA 
 (13.6 mi)
978-538-4000
Languages Spoken:
English
See accepted insurances

Zachary Spigelman is a Hematologist Oncology specialist and a Hematologist in Peabody, Massachusetts. Dr. Spigelman and is rated as a Distinguished provider by MediFind in the treatment of Carney Complex. His top areas of expertise are Thrombocytopenia, Small Cell Lung Cancer (SCLC), Schnitzler Syndrome, and Monoclonal Gammopathy of Undetermined Significance (MGUS).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cote's expertise for a condition
ConditionClose
View All 19 Distinguished Conditions
View All 12 Advanced Conditions
View All 44 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile